One approach to categorizing patients using chest computed tomography (CT) imaging manifestations of pulmonary sarcoidosis is into three classifications: fibrotic, non-fibrotic, or no parenchymal abnormality. We aimed to evaluate the relationships between these imaging subtypes and demographic and physiologic variables in a large group of sarcoidosis patients with chest CT.

Weight loss improves upper airway collapsibility in people with OSA. However, it is unclear how weight loss affects the other physiological traits (ie, endotypes) associated with OSA (loop gain, arousal threshold, and muscle compensation).

Targeted proximal hypoglossal nerve stimulation (THN, pHGNS) improved sleep-disordered breathing, sleep architecture, and quality of life (QOL) with a favorable safety profile over 1 year in the THN3 randomized, controlled trial. Herein, THN3 pHGNS 3-year safety and efficacy are profiled with reference to distal HGNS (dHGNS) from the STAR trial.

Pulmonary arterial hypertension (PAH) is a progressive disease associated with high morbidity and mortality. Traditional assessments such as the 6-minute walk distance (6MWD) may not adequately capture daily physical activity or patient experience in real-world settings.

Multiple clinical and inflammatory risk factors for asthma attacks have been identified, including attack history, comorbidities, blood eosinophil count (BEC), and exhaled nitric oxide (Feno). However, the impact of sex on their prognostic value is unclear.

Rhabdomyolysis is the clinical syndrome resulting from the release of skeletal muscle cellular contents into the bloodstream, typically manifesting as limb weakness, myalgias, swelling, myoglobinuria, electrolyte abnormalities, and, critically, acute kidney injury (AKI). Recognition of this complex of clinical and biochemical features is necessary for accurate diagnosis and subsequent management.

Pulmonary hypertension (PH) is a complication of advanced cystic fibrosis (CF) and non-cystic fibrosis bronchiectasis (n-CFB). The prevalence and after transplantation prognostic significance of PH in CF and n-CFB remain poorly defined.

The way in which risk predictors combine and contribute to severe asthma exacerbations may differ between clinical trials and real-world settings.

Use of nonphysician alternative care providers (ACPs) can improve timely access to sleep-disordered breathing (SDB) care, and previous studies have demonstrated beneficial short-term clinical outcomes. Longer-term clinical and economic impacts of an ACP model for patients with severe SDB have not been evaluated.

Because lung cancer risk remains elevated beyond 15 years after smoking cessation, the American Cancer Society (ACS) recommended in 2023 to remove the quit duration criterion from the United States Preventive Services Taskforce (USPSTF) lung cancer screening guidelines.

Previous studies have shown inconsistent results regarding the use of proton pump inhibitors (PPIs) and the risk on exacerbations in patients with chronic obstructive airway diseases (COADs).

Chronic respiratory diseases (CRDs) remain one of the leading causes of preventable morbidity and disability worldwide, affecting up to one-third of the total Western population in 2025. Recognizing the substantial burden of inflammatory airway diseases such as asthma, COPD, chronic rhinosinusitis, and respiratory allergy, the European Forum for Research and Education in Allergy and Airway diseases (EUFOREA) organized the symposium "Shaping the Future of Respiratory Care" in April 2025 in Brussels, Belgium, at the occasion of the 10-year jubilee. Featuring keynote speakers from the World Health Organization and EUFOREA, this initiative had the following aims: (1) promoting dialogue on translating innovations into daily clinical practice; (2) encouraging collaboration between the different stakeholders in the respiratory field; and (3) defining strategic priorities to transform respiratory care and arrest the CRD epidemic over the next decade. The symposium highlighted the importance of moving toward predictive, preventive, and patient-centered medicine, while supporting value-based health care systems to improve long-term patient outcomes. This report summarizes the main insights and strategic directions discussed at the meeting.

Bronchiectasis and pulmonary nontuberculous mycobacteria (NTM) infections are chronic diseases that can cause debilitating respiratory symptoms, exacerbations, and even lead to respiratory failure. Clinical care has historically been provided by individual specialists, but multidisciplinary care teams have recently emerged to improve evaluation of underlying etiology and interventions that disrupt the trajectory of disease progression.

We report the case of a 45-year-old woman who was referred to our Cardiology Department because of persistent exertional dyspnea and peripheral edema. She had an established clinical diagnosis of hereditary hemorrhagic telangiectasia with multiple gastrointestinal telangiectasias that had been submitted to repeat embolization in the past and arteriovenous malformations in the liver and lungs. Complete blood count was diagnostic for severe anemia (hemoglobin 5-6 g/dL). Since the hereditary hemorrhagic telangiectasia diagnosis 3 years prior, the patient informed us that she has undergone 27 blood transfusions and multiple embolizations to manage gastrointestinal telangiectasias. Given her severe anemia that was caused by gastrointestinal telangiectasia, treatment with bevacizumab was initiated. Bevacizumab was administered over 8 cycles (initially biweekly for 4 doses, followed by monthly administration).

Osteoporosis is an important cause for morbidity, but it remains underdiagnosed, and current screening programs for osteoporosis are underused.

Chronic thromboembolic pulmonary hypertension (CTEPH) is a form of pulmonary hypertension characterized by unresolved thromboemboli and subsequent fibrotic obstructions of the pulmonary arteries. Pulmonary thromboendarterectomy (PTE) is the treatment of choice if feasible. Multidisciplinary evaluation by an experienced CTEPH team is essential to ensure proper patient selection, operability assessment, and appropriate perioperative management of patients with high-risk hemodynamics and right ventricular failure. In the early postoperative period, close monitoring in the ICU is necessary. These patients are at risk for profound oxygenation and hemodynamic derangements after PTE surgery. Inotropic support, diuresis, mechanical ventilation with adequately large tidal volumes, and supportive care for potential complications such as reperfusion lung injury or airway hemorrhage are at the core of ICU management. Anticoagulation is a key cornerstone of CTEPH treatment and must be started as soon as possible, while carefully weighing the risks of bleeding complications vs rethrombosis. Follow-up evaluation after pulmonary endarterectomy is essential to evaluate for residual pulmonary hypertension and identify patients who may benefit from additional treatments. Ultimately, optimal outcomes depend on an experienced multidisciplinary CTEPH team with an approach to care that spans the preoperative, early postoperative, and after discharge phases. This review aims to provide clinicians with practical guidance for the perioperative management of patients with CTEPH undergoing PTE surgery.

The prevalence of e-cigarette use is increasing, and e-cigarette users with no history of tobacco smoking report greater respiratory symptoms. Traditional evaluation of resting pulmonary function may fail to detect subclinical abnormalities.

Invasive candidiasis (IC) is a common complication in patients in ICUs. IC can be divided into bloodstream infections (candidemia) and deep-seated infections. Candida infections are associated with high mortality and longer hospital stays. Moreover, the emergence of Candida auris and other species prone to cause ICU outbreaks highlights the importance of this pathogen.